SCHEMBL4656260

SCHEMBL4656260

N#CC(C#N)=Cc1ccc(Cl)c(Cl)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 10/20 0.61
▸ KMT2A Q03164 9/20 0.61
▸ MAPT P10636 9/20 0.61
▸ MEN1 O00255 8/20 0.61
▸ KDM4E B2RXH2 5/20 0.61
▸ LMNA P02545 4/20 0.61
▸ NPSR1 Q6W5P4 3/20 0.61
▸ POLB P06746 2/20 0.61
▸ EGFR P00533 6/20 0.58
▸ CYP3A4 P08684 4/20 0.58
▸ HPGD P15428 4/20 0.58
▸ BLM P54132 4/20 0.58
▸ TSHR P16473 3/20 0.58
▸ NFKB1 P19838 3/20 0.58
▸ PMP22 Q01453 3/20 0.58
▸ CYP1A2 P05177 3/20 0.58
▸ CYP2C9 P11712 3/20 0.58
▸ HSD17B10 Q99714 3/20 0.58
▸ SMN1; SMN2 Q16637 3/20 0.58
▸ TP53 P04637 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15298231 0.83 MEN1 (0.55) ALDH1A1KMT2AMAPTMEN1KDM4E
SCHEMBL8539257 0.83 KMT2A (0.55) ALDH1A1KMT2AMAPTMEN1KDM4E
SCHEMBL19002450 0.81 ALDH1A1 (0.54) ALDH1A1KMT2AMAPTMEN1KDM4E
SCHEMBL13485332 0.79 ESR1 (0.58) ALDH1A1KMT2AMAPTMEN1KDM4E
SCHEMBL15286783 0.79 ALDH1A1 (0.50) ALDH1A1KMT2AMAPTMEN1KDM4E
SCHEMBL15298179 0.79 ALDH1A1 (0.50) ALDH1A1KMT2AMAPTMEN1KDM4E
SCHEMBL19002185 0.78 KMO (0.51) ALDH1A1KMT2AMAPTMEN1KDM4E
SCHEMBL18992629 0.78 APP (0.45) ALDH1A1KMT2AMAPTMEN1KDM4E
SCHEMBL17466932 0.78 MAPT (1.00) ALDH1A1KMT2AMAPTMEN1KDM4E
SCHEMBL11313166 0.77 ALDH1A1 (0.70) ALDH1A1KMT2AMAPTMEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013144191-A1 SUBSTITUTED 2-AMINO-3-CYANOPYRIDINES AS INHIBITORS OF SODIUM-CALCIUM EXCHANGE AND USE THEREOF FOR CARDIOVASCULAR DISEASES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-10-03 — — WO disclosed
EP-1385817-B1 MALONONITRILE COMPOUNDS AND THEIR USE AS PESTICIDES SUMITOMO CHEMICAL CO (JP) 2008-12-03 — — EP disclosed
US-7402691-B2 Malononitrile compounds and their use as pesticides SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-07-22 — — US disclosed
US-7011838-B2 Malononitrile compounds and their use as pesticides SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-03-14 — — US disclosed
US-20050209323-A1 Malononitrile compounds and their use as pesticides OTAKA KEN 2005-09-22 — — US disclosed
US-20050182105-A1 Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function BRISTOL-MYERS SQUIBB COMPANY 2005-08-18 — — US disclosed
US-20040143007-A1 Malononitrile compounds and their use as pesticides SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2004-07-22 — — US disclosed
US-20040142821-A1 Pesticide composition comprising malononitrile compounds SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2004-07-22 — — US disclosed
US-20040138065-A1 Malononitrile compounds and their use as pesticides SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2004-07-15 — — US disclosed
EP-1004584-A2 Pyranoquinoline derivatives as inhibitors of cell proliferation ELI LILLY AND COMPANY LIMITED (GB) 2000-05-31 — — EP disclosed
US-5434160-A Autoimmune diseases; prevention of excess cell proliferation or enzyme release LILLY INDUSTRIES LIMITED (GB) 1995-07-18 — — US disclosed
EP-0599514-A2 Pyranoquinoline derivatives as inhibitors of cell proliferation LILLY INDUSTRIES LIMITED (GB) 1994-06-01 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050209323-A1 Malononitrile compounds and their use as pesticides C1S, C1R, C5 ALDH1A1 1502/4885KMT2A 3658/4885MAPT 4314/4885
US-20040143007-A1 Malononitrile compounds and their use as pesticides MAL2, ME1, CBR3 ALDH1A1 1262/4885KMT2A 3236/4885MAPT 4273/4885
US-20040138065-A1 Malononitrile compounds and their use as pesticides CBR1, MAL2, CBR3 ALDH1A1 614/4885KMT2A 2762/4885MAPT 4612/4885
US-20050182105-A1 Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function NR3C2, NR4A3, NR3C1 ALDH1A1 2565/4885KMT2A 1462/4885MAPT 4827/4885
US-20040142821-A1 Pesticide composition comprising malononitrile compounds CBR1, CBR3, ME1 ALDH1A1 867/4885KMT2A 3427/4885MAPT 4249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback